Responsible Center: NASA JSC
Grant Monitor: Whitmore, Mihriban
Center Contact: 281-244-1004 mihriban.whitmore-1@nasa.gov
Unique ID: 9452
|
Solicitation / Funding Source: 2012 Crew Health NNJ12ZSA002N
Grant/Contract No.: NNX13AR16G
Project Type: Ground
Flight Program:
TechPort: No |
No. of Post Docs: 0
No. of PhD Candidates: 0
No. of Master's Candidates: 0
No. of Bachelor's Candidates: 0
|
No. of PhD Degrees: 0
No. of Master's Degrees: 0
No. of Bachelor's Degrees: 0
|
|
Human Research Program Elements: |
(1) SHFH:Space Human Factors & Habitability (archival in 2017)
|
|
Human Research Program Risks: |
(1) Medical Conditions:Risk of Adverse Health Outcomes and Decrements in Performance Due to Medical Conditions that occur in Mission, as well as Long Term Health Outcomes Due to Mission Exposures (2) Microhost:Risk of Adverse Health Effects Due to Host-Microorganism Interactions
|
|
Human Research Program Gaps: |
(1) Medical-501:We need to develop integrated exploration medical system models for the Moon and Mars. (2) Micro-101:Evaluate the effects of isolation, confinement and weightlessness on changes in the vehicle microbiome, the human microbiome, and microbial virulence. (3) Micro-102:Evaluate whether deep-space radiation has an additive or synergistic effect with weightlessness/isolation/confinement on microbial types, numbers, and virulence. (4) Micro-103:Evaluate whether atmospheric composition, such as elevated CO2 levels or mildly hypoxic exploration atmospheres, are a significant contributor to changes in the microbial profile of spaceflight. (5) Micro-201:Micro-201: Evaluate the contribution of changes in microbial numbers, types, and virulence on the likelihood and consequence of adverse health events (infection), during the mission.
|
|
Task Description: |
Understanding the impact of the spaceflight environment on the disease-causing potential of a wide variety of pathogenic and commensal microbes is critical for ensuring crew health, safety, and performance. Changes that occur to both the immune system of astronauts and pathogenesis of microbes during spaceflight could represent a formidable challenge to the successful transition from short-to-long duration missions. This is a critical issue to address since a) the crew’s immune system is dysfunctional during flight, and b) results from our collaborative team and others have demonstrated that spaceflight and/or spaceflight-analogue culture globally alters the virulence, gene expression, and/or pathogenesis-related phenotypes of several microbial pathogens. This proposal aims to further improve infectious disease risk assessment for astronauts by investigating the likelihood that a variety of microorganisms may exhibit alterations in virulence in response to the microgravity environment. We will accomplish this by profiling changes in virulence, persistence in the host, and targeted changes in gene expression of a select panel of pathogenic and commensal microorganisms exposed to spaceflight-analogue culture using the Rotating Wall Vessel (RWV) bioreactor. Microbes proposed for this study include 1) Salmonella Typhimurium, 2) Staphylococcus aureus, 3) a Space Shuttle environmental isolate of Burkholderia cepacia, and 4) Lactobacillus acidophilus, a commensal microorganism. The nematode Caenorhabditis elegans (C. elegans) will be used as a human surrogate model of infection to evaluate changes in microbial virulence in response to RWV culture and will also be profiled for targeted changes in the expression of genes important for host immunity. Moreover, as astronauts have dysfunctional immune systems during spaceflight, the susceptibility of an immunocomprised C. elegans mutant to infection with these same microbes will also be evaluated. Results from this work hold potential to provide deeper insight into the likelihood, consequence, and respective uncertainties of this HRP risk. |
|
Research Impact/Earth Benefits: |
This research will broaden our knowledge of the host-pathogen interaction that leads to infectious disease, and will provide fundamental new insight into mechanisms important for the development of new therapeutic strategies to combat infectious disease for the general public. |